在芬兰基于人口的队列中,高血糖和膀癌的预后
Lauri Vuoristo1, Antti Pöyhönen2, Silja M Vuorlaakso1
1Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.
PloS one
|December 12, 2025
概括
糖尿病与更糟糕的膀癌 (BCa) 结果有关. 糖尿病BCa患者的低血糖控制增加了BCa特定和整体死亡风险.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 糖尿病是膀癌 (BCa) 发病率和死亡率的潜在危险因素.
- 了解糖尿病对BCa预后的影响对于患者管理至关重要.
研究的目的:
- 为了研究糖尿病和膀癌的预后之间的联系.
- 评估血糖状况和抗糖尿病药物如何影响BCa结果.
主要方法:
- 一项基于注册的队列研究,对芬兰14,638名膀癌患者进行了研究 (1995-2012).
- 三个数据库的数据链接,提供关于BCa,糖尿病和并发症的信息.
- 用多变量考克斯回归模型来评估死亡风险.
主要成果:
- 糖尿病与膀癌特异性和整体死亡率明显恶化有关.
- 诊断后血糖水平升高与死亡风险增加相关 (HR为BCa特定的1.58,HR为整体的1.50).
- 在两性中都观察到增加的风险,突出显示糖尿病对BCa预后的持续负面影响.
结论:
- 糖尿病和血糖控制不佳是膀癌患者死亡率增加的重要风险因素.
- 这些发现强调了在被诊断为膀癌的个体中管理糖尿病的重要性,以潜在地提高生存率.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505


